John Kealy

John Kealy

Company: Ulysses Neuroscience Ltd.

Job title: CSO & Head of Ulysses Maynooth


Psychedelics 2.0 – Novel preclinical approaches to investigate mechanisms of action and efficacy of glutamatergic and serotonergic psychedelics 9:15 am

Acute and long-term behavioural and molecular efficacy of ketamine in the rat IFN-alpha model of depression Exploring changes in synaptic markers (BDNF; pre-synaptic SV2A and synaptophysin; post-synaptic PSD-95 and spinophilin) induced by psychedelics Using established and innovative behavioural endpoints to understand psychedelic effects on brain function Preclinical electrophysiology as a translational biomarker of acute and…Read more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.